Corcept Therapeutics Inc
NASDAQ:CORT

Watchlist Manager
Corcept Therapeutics Inc Logo
Corcept Therapeutics Inc
NASDAQ:CORT
Watchlist
Price: 57.54 USD 2.9% Market Closed
Market Cap: 6B USD
Have any thoughts about
Corcept Therapeutics Inc?
Write Note

Corcept Therapeutics Inc
Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Corcept Therapeutics Inc
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Corcept Therapeutics Inc
NASDAQ:CORT
Common Stock
$135k
CAGR 3-Years
11%
CAGR 5-Years
6%
CAGR 10-Years
3%
Johnson & Johnson
NYSE:JNJ
Common Stock
$3.1B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Bristol-Myers Squibb Co
NYSE:BMY
Common Stock
$292m
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
3%
Pfizer Inc
NYSE:PFE
Common Stock
$480m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Merck & Co Inc
NYSE:MRK
Common Stock
$1.8B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Eli Lilly and Co
NYSE:LLY
Common Stock
$593.9m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
-2%
No Stocks Found

Corcept Therapeutics Inc
Glance View

Market Cap
6B USD
Industry
Pharmaceuticals

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. The company is headquartered in Menlo Park, California and currently employs 238 full-time employees. The company went IPO on 2004-04-15. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The company has marketed Korlym (mifepristone) for the treatment of patients suffering from Cushing’s syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Its cortisol activity can be modulated by a drug that competes with cortisol as it attempts to bind to the glucocorticoid receptor (GR). The Company’s ingredient, mifepristone, reduces the binding of excess cortisol to GR. Its compounds bind to GR but not the progesterone, estrogen, or androgen receptors.

CORT Intrinsic Value
63.25 USD
Undervaluation 9%
Intrinsic Value
Price

See Also

What is Corcept Therapeutics Inc's Common Stock?
Common Stock
135k USD

Based on the financial report for Sep 30, 2024, Corcept Therapeutics Inc's Common Stock amounts to 135k USD.

What is Corcept Therapeutics Inc's Common Stock growth rate?
Common Stock CAGR 10Y
3%

Over the last year, the Common Stock growth was 35%. The average annual Common Stock growth rates for Corcept Therapeutics Inc have been 11% over the past three years , 6% over the past five years , and 3% over the past ten years .

Back to Top